about
Covariate pharmacokinetic model building in oncology and its potential clinical relevance.Accuracy of the Pepin method to determine appropriate lithium dosages in healthy volunteersPopulation pharmacokinetics of amphotericin B in children with malignant diseasesPopulation pharmacokinetics of carbamazepine in Singapore epileptic patientsLewis Sheiner ISoP/UCSF Lecturer Award: From Drug Use to Statistical Models and Vice VersaPredicting bee community responses to land-use changes: Effects of geographic and taxonomic biasesAn acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.Caffeine in apnoeic Asian neonates: a sparse data analysis.A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data.Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants.Population pharmacokinetic investigation of disopyramide by mixed effect modelling using routine clinical pharmacokinetic data in Japanese patients.Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgeryLean body mass: the development and validation of prediction equations in healthy adultsA comparative evaluation of models to predict human intestinal metabolism from nonclinical data.Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: volume of distribution at steady state.Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal functionEstimation of lean body weight in older community-dwelling menAbacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.Reliability and validity of the new Tanaka B Intelligence Scale scores: a group intelligence test.Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population.Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants: an update.Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis.A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.Population pharmacokinetic analysis of vancomycin in patients with hematological malignanciesCharacterizing plasma albumin concentration changes in TB/HIV patients on anti retroviral and anti -tuberculosis therapy.Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk.The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance.Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline.Bayesian derived predictions for twice daily theophylline under outpatient conditions and an assessment of optimal sampling times
P2860
Q27687599-61B45347-68F3-4E23-BD27-7B7DE9DBABBEQ28361176-FB9A935E-A26C-4216-A309-3F906F7D3F3CQ28365933-B4A4DB99-ED5B-4948-8876-24C85FED6C19Q28367563-2FB19D35-93D0-40E2-BC46-84F5FE2ECC7CQ28652486-2B5CBF80-A53A-4D57-82FE-599CE2323CCDQ30276154-91C7C043-EB38-4E8D-85A9-7603E1BBF2CCQ30558676-4FECDB57-9E09-46AC-B2C4-53B9906C9A3CQ30701613-75787A73-18E7-447F-9325-B52570632301Q30786488-4C66726C-98E5-45A7-9B44-51DBE8B7C210Q30841908-32A64353-FCE7-4911-92AB-04898F686DDFQ30841916-9635B8E4-D443-4DAF-A7E1-49B6E8CD0596Q30909557-C74B881D-A3A9-4B5E-BABC-E53CBB15B52AQ30986505-173FA314-3F4A-492A-B450-B9003B2900C2Q30993137-C5DD9937-C456-4C0F-B929-3E431F9F7A11Q31012256-E27773B7-A70D-4761-BD14-DE6082FDFB26Q31144236-09B8F443-1D31-4EBA-9BD7-566D460C85FCQ31150922-1373CBEE-5BC4-4D7A-8767-BD6F489B6D12Q31159063-88E97B57-CFDA-4A1A-AFC4-CAE789C05335Q33188075-CDE6C873-8ADA-4095-9A13-5022920BD06EQ33388177-7C35F30A-5865-47B1-B4C3-827754E9808FQ33613764-EB585F2D-97E6-4C34-BA69-10F990F6F121Q33668185-2FF966D4-C6B4-4442-AD65-0F281150653DQ33720839-227910DF-37CC-4356-A30A-E22A9AFAE09DQ33764995-D3D09FC9-9979-40C1-9ADC-AC107ED7B9A9Q33774034-B6A9A064-186B-428A-8066-AFFFD3DB68ADQ33802477-2BBF3D51-8D7E-452B-A51D-1890F97280CEQ33888004-CDEEA414-4BF6-461A-BFE1-9F014616F405Q33926436-3AF6631E-7495-43D2-89B1-FF19AB00B5D4Q33978650-F23B706E-497B-4ECD-9982-6C938952B7D2Q34056530-2759CCDB-3F2C-46E6-92D6-844CD52BAAFCQ34145251-A6CBD7FC-D07F-41F1-9C55-BFC89DFC7EDDQ34152549-9B75821B-C916-4E69-82F8-BA13257FB461Q34210712-65962AE6-215D-43B3-8980-05A863C8734AQ34228227-799AC9D1-3E3F-46DC-92FD-778C82FF042FQ34235116-09C6212A-2FF9-47BE-AE11-D705DAEA963FQ34287623-83B7709A-6356-4853-BEF4-342E670434CDQ34347407-4F6589D3-4063-4A62-BC08-5DE070232278Q34358674-7D6039F1-A739-488A-9A51-31B907DEE3DCQ34381352-756AD476-AAAA-43C1-9DCE-F6A39EE52026Q34397240-C16EA9B2-4328-4574-BA08-F7C096E5A66B
P2860
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年学术文章
@wuu
1981年学术文章
@zh
1981年学术文章
@zh-cn
1981年学术文章
@zh-hans
1981年学术文章
@zh-my
1981年学术文章
@zh-sg
1981年學術文章
@yue
1981年學術文章
@zh-hant
name
Some suggestions for measuring predictive performance.
@en
Some suggestions for measuring predictive performance.
@nl
type
label
Some suggestions for measuring predictive performance.
@en
Some suggestions for measuring predictive performance.
@nl
prefLabel
Some suggestions for measuring predictive performance.
@en
Some suggestions for measuring predictive performance.
@nl
P356
P1476
Some suggestions for measuring predictive performance.
@en
P2093
P2888
P304
P356
10.1007/BF01060893
P577
1981-08-01T00:00:00Z